Focus Rheums| ACR Convergence 2024 Previews

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: health insurance

Crossing the Line

When Medical Workforce Grievances Lead to Strikes

  |  

Picket Lines: June 27 was marked on my calendar as the day to watch. No doubt the union organizers shrewdly selected it to be their strike day because of its proximity to July 1, an auspicious date for teaching hospitals, when rookie interns and residents anxiously assume their heightened roles of responsibility within the medical…

Ethics Forum: Prescribing Teratogenic Medications to Adolescents Can Raise Confidentiality, Ethical Concerns

Karen B. Onel, MD, & Melissa Tesher, MD  |  

Case A 17-year-old girl returns to the rheumatology clinic for scheduled follow-up for systemic lupus erythematosus (SLE). She is accompanied by her mother and father. She has a history of autoimmune cytopenias and Class III lupus nephritis. She has responded well to treatment with mycophenolate mofetil and hydroxychloroquine and was successfully weaned off of prednisone…

Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

  |  

The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to Seoyoung…

Blacks, Asians at Higher Risk for Allopurinol-Related Skin Reactions

Deborah Levenson  |  

Be careful when prescribing allo­purinol to black and Asian gout patients, a study newly advises. Black and Asian patients who take this ubiquitous, more-than-40-year-old medication are at much higher risk of certain serious skin reactions than are Caucasians or Hispanics. Compared with Caucasians, blacks who take allopurinol to lower blood urate levels have an increased…

Placebo Outperforms Glucosamine/Chondroitin Sulfate for Knee OA

Erin Blakemore  |  

(Reuters Health)—Glucosamine sulfate and chondroitin sulfate are not more beneficial than placebo treatments for patients with knee osteoarthritis, a recent trial suggests. In a double-blind study, researchers investigated the efficacy of a medicine that delivered both glucosamine and chondroitin sulfate. The 164 participants all had osteoarthritis and moderate to severe knee pain. Half the participants…

Prior Authorization Reform Achieves Some Success

Ryan Larosa, ACR staff  |  

In early August, the American Medical Association (AMA) held its annual state advocacy strategy meeting in Chicago. This meeting pulls together all state medical societies and national specialty organizations. Over three days, participants engage in roundtable discussions on issues, solutions and best practices for health policy. Networking opportunities abound. The meetings showcase legislation that has…

HIPAA Audit Activities Increase in 2016

  |  

In the coming months, rheumatologists may want to pay particular attention to their email inboxes. By the end of the year, the Department of Health and Human Services (HHS) Office for Civil Rights (OCR) will complete stage I, phase II of a series of desk and on-site audits designed to assess providers and their business…

The ACR and Partners Help Get Legislation Passed in New York to Limit Step Therapy

  |  

In June, state lawmakers in New York passed legislation on step therapy designed to help ensure patient access to the best and most appropriate care. Step therapy mandates that a patient with a specific condition receive prescribed drugs approved for that condition in the order that an insurance company determines it will cover as the…